|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In the 2016 WHO classification of diffuse glioma, the diagnosis of an (anaplastic) oligodendroglioma requires the presence of both an IDH mutation (mt) and 1p/19q codeletion, whereas (anaplastic) astrocytoma are divided in IDH wild-type and IDHmt tumors.
|
30072066 |
2018 |
|
Anaplastic Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
CTD_human |
We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma.
|
20160062 |
2010 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the effect of IDH1 mutations on progression-free survival and overall survival (OS), and its correlation with other clinical and molecular features in the prospective randomized European Organization for Research and Treatment of Cancer study 26951 on adjuvant procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea, and vincristine (PCV) in anaplastic oligodendroglioma.
|
20160062 |
2010 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Not only morphological and immunohistochemical examinations, but also cytogenetical investigations for IDH1/2 mutation, 1p/19q loss, and PTEN alteration, are strongly supportive methods for the differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma.
|
23979650 |
2014 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study indicates that the combination of sequential treatment with radiation and temozolomide might provide a favorable outcome in the case of 1p/19q-codeleted spinal anaplastic oligodendrogliomas and that molecular analysis can be beneficial in guiding treatment strategies, although the impact of IDH mutations on these tumors is still unclear.
|
26352098 |
2016 |
|
Anaplastic Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Today, the diagnosis of anaplastic oligodendroglioma requires the presence of both IDH-mt and 1p/19q co-deletion, whereas anaplastic astrocytoma is divided into IDH wild-type ( IDH-wt) and IDH-mt tumors.
|
28640702 |
2017 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For each histopathologic diagnosis, the number of cases and positive rate of c-Met expression are as follows: oligodendroglioma, IDH-mutant, and 1p19q codeletion (OD): 16 cases, 6.3%; anaplastic oligodendroglioma, IDH-mutant, and 1p19q codeletion (AO): 11 cases, 36.4%; diffuse astrocytoma (DA), IDH-mutant: 21 cases, 28.6%; anaplastic astrocytoma (AA), IDH- mutant: 15 cases, 20%; glioblastoma, IDH-mutant: 2, 100%, DA, IDH-wildtype: 9 cases, 33.3%; AA, IDH-wildtype: 20 cases, 30.0%; and glioblastoma, IDH-wildtype: 59 cases, 52.5%. c-Met expression was correlated with progression-free survival in oligodendroglial tumors and glioblastoma, IDH-wildtype.
|
30878754 |
2019 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The R132H IDH1 mutation was identified in 43/117 tumor samples and R172K IDH2 mutation was detected in only one anaplastic oligodendroglioma.
|
27268645 |
2016 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To help determine the molecular mechanism behind this prognostic effect, we have conducted genome-wide methylation profiling and determined the MGMT promoter methylation status, 1p19q LOH, IDH1 mutation status, and expression profile on a series of oligodendroglial tumors [anaplastic oligodendrogliomas (AOD) and anaplastic oligoastrocytomas (AOA)] within EORTC study 26951.
|
21914791 |
2011 |
|
Anaplastic Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combining two biomarkers, IDH1/2 and 1p/19q codeletion, makes it possible to stratify AO in three groups with very distinct prognostic features.
|
23681562 |
2013 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Studies have identified several molecular abnormalities with clinical or biological relevance to AOD (e.g. t(1;19)(q10;p10), IDH1, IDH2, CIC and FUBP1 mutations).To better characterize the clinical and biological behavior of this tumor type, the creation of a national multicentric network, named "Prise en charge des OLigodendrogliomes Anaplasiques (POLA)," has been supported by the Institut National du Cancer (InCA).
|
23071531 |
2012 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, no specific imaging pattern could be identified for the 1p/19q-codeleted AO or the IDH-mutated AO.
|
24353325 |
2014 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both 1p19q codeletion and IDH-1 mutation predict outcome of patients with both oligodendroglioma and AO.
|
22396073 |
2012 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AOA1 with 1p/19q codeletion and/or IDH1/2 mutation showed similar Kaplan-Meier plots with AO (P = .169 for PFS and P = .523 for OS).
|
23486687 |
2013 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
From our results, IDH1 mutation was an independent positive prognostic factor in LOs and AOs, especially in the absence of p53 overexpression.
|
22922798 |
2012 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic oligoastrocytoma and anaplastic astrocytoma patients with IDH gene mutation showed similar prognosis with anaplastic oligodendroglioma patients with wild-type IDH gene.
|
24149775 |
2014 |
|
Anaplastic Oligodendroglioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also showed that MGMT methylation and 1p/19q co-deletion rather than IDH1 mutations were prognostic factors for Group 2 patients (AOA + AO).
|
24160898 |
2013 |
|
Anaplastic Oligodendroglioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the six IDH1 positive cases, three were glioblastomas (IV), and one each were anaplastic oligoastrocytoma (III), anaplastic oligodendroglioma III (n=1) and diffuse astrocytoma.
|
24460285 |
2013 |